Dr. Colm Henry:

Yes, it rejected it last week based on cost-effectiveness. Given the importance of this issue, the fact that other jurisdictions have approved the drug and the absence of treatment for the particular cohort suffering from type 1 spinal muscular atrophy, the HSE leadership will deal with this in June.